Compare Repligen Corporation Common Stock (RGEN) vs Targa Resources Inc. Common Stock (TRGP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Targa Resources Inc. Common Stock — how do they compare? Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B), while Targa Resources Inc. Common Stock trades at $290.9 (market cap $62.38B). The key difference: Targa Resources Inc. Common Stock is far larger — about 5.5× Repligen Corporation Common Stock's market cap, and Targa Resources Inc. Common Stock pays a 1.72% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Targa Resources Inc. Common Stock for 5 Days on average.
| RGEN | TRGP | |
|---|---|---|
Market Cap | $11.31B | $62.38B |
Volume | 1,216,919 | 882,213 |
Sector | Health | Energy |
52-Week High | $194.57 | $302.25 |
52-Week Low | $102.87 | $146.30 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $11.20B | $81.83B |
Dividend Yield | — | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TRGP trades at $293.04, up 0.86% today, with a bullish technical signal driven by moving averages and a consensus analyst price target of $329.54. The company reported strong Q2 2026 EPS of $3.54, beating expectations, and maintains robust profitability with a net income margin of 13.54% and ROE of 72.27%. Recent news highlights a $1.25 quarterly dividend and sustainability reporting, reflecting stable operations.
The outlook is positive given earnings beats, high analyst buy ratings (82%), and projected revenue growth, though risks include commodity price exposure and high debt-to-asset ratio of 68.07%. The stock's current price near the analyst low target of $294.00 suggests potential upside if fundamentals hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Targa Resources Inc. Common Stock
Targa Resources provides midstream infrastructure for natural gas and natural gas liquids. Its services include gathering, processing, transportation, fractionation, storage, and export logistics.
Read more on TRGP →
